MSD begins Phase III trial of dengue vaccine

Merck & Co (MSD) has initiated the randomised MOBILIZE-1 Phase III trial to assess the immunogenicity, efficacy, and safety of the investigational quadrivalent vaccine, V181, designed to prevent dengue disease.
The disease is caused by any of the four serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.
Also referred to as V181-005, the study has started enrolling its first subjects in Singapore.
The placebo-controlled, double-blind trial aims to enrol approximately 12,000 healthy individuals aged two to 17 years old.
They will be randomised and given either a single dose of the vaccine or a placebo. More than 30 trial sites across dengue endemic regions in the Asia-Pacific, including Indonesia, the Philippines, Singapore, Thailand and Vietnam, are planned to be part of the trial.
The trial's primary goal is to determine the efficacy and safety of a single dose of the vaccine in preventing symptomatic virologically confirmed dengue (VCD) of any severity, caused by any dengue serotype, and without consideration of previous dengue exposure.
A key secondary efficacy endpoint is the evaluation of V181's ability to prevent symptomatic VCD caused by each serotype.
Additional secondary goals of the trial include the assessment of V181 in preventing symptomatic VCD with severe VCD, warning signs, and hospitalisation due to dengue.
The live attenuated quadrivalent vaccine is intended to be administered in one dose.
MSD Research Laboratories' global clinical development infectious diseases and vaccines senior vice-president Dr Paula Annunziato said: 'Approximately half of the world's population lives in areas with a risk for dengue, making it a serious public health threat.
'The initiation of the MOBILIZE-1 study, the first Phase III trial in our clinical development programme, marks a key milestone in our work to help address this widespread mosquito-borne disease.
'If successful, V181 could provide an important single-dose option for at-risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe.'
MSD's investigational KRAS G12C inhibitor has recently shown signs of anti-tumour activity when used both alone and in combination with other oncology drugs.
"MSD begins Phase III trial of dengue vaccine" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Boston Globe

38 minutes ago

• Boston Globe

Mass. Black therapists trying to diversify the workforce face an uphill battle

Advertisement 'We took the good and left the bad, and helped create this,' Labissiere, one of the clinic's cofounders, said from the Hyde Park Avenue office. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Labissiere and Wynn are rarities in this grueling industry: Black clinicians who have stuck around and own their own practice. The Child and Family Wellness Center isone of just a few Black-owned behavioral health practices in Massachusetts. In interviews with the Globe, 10 Black mental health care providers, advocates, and public officials agreed several systemic barriers keep the workforce from diversifying. The deep-seated stigma of mental illness among Black people, the time and financial costs of finishing school, and the biases embedded in the field's license exams are roadblocks for diversifying the workforce, which already suffers from massive turnover and vacancy rates. Related : Advertisement The societal costs are immense. The experienced these symptoms at higher rates, said Gemima St. Louis, vice president for workforce initiatives and specialty training and clinical psychology professor at Williams James College in Newton. As the mental health crises that COVID-19 drew out persist, stakeholders worry the behavioral health workforce won't be able to meet this rising demand with culturally competent care. 'We have a workforce that is insufficient, a workforce that lacks the diversity that is represented in the communities that have the greatest needs for mental health services,' St. Louis said. Related : Advocates are introducing measures to tackle the representation gap at its root. Clinicians working in underserved communities can have some of their student debt covered through The people working to diversify the behavioral health workforce are chipping away at a profession that has historically been for white and affluent individuals. A 2023 Advertisement One in 10 respondents in behavioral health leadership roles identified as non-Hispanic Black. Black respondents made up 9 percent of the survey's independently licensed clinicians, meaning they don't need supervision to provide treatment. Only 7.6 percent of behavioral health physicians — professionals with medical degrees — were Black. The lack of representation within the sector doesn't match the range of people needing these services, advocates say. A separate survey of insured residents across Massachusetts found that one in 10 non-Hispanic Black residents reported poor mental health in 2021, along with 15 percent of Hispanic residents. One barrier driving these disparities precedes any roadblocks Black clinicians are facing in their field: mental health care's taboo nature in their community. Black people 'might have a little bit more wealth and more opportunities, but we've never really had a chance to really process our struggles in this country,' said Nieisha Deed, founder of Recruitment into the sector can be happenstance, instead of something instilled from an early age. Larry Higginbottom, CEO of The Osiris Group clinic in Roxbury, stumbled across 'the mental health field' during a chance conversation in the late '80s with Omar Reid, a local pioneer of Black psychology and mental health. Advertisement It was a foreign concept, but '[Reed] planted a seed,' Higginbottom, now 71, said. For Melanie Robinson Findlay, owner of Upwards 'N' Onwards, an independent therapy practice in Hyde Park, the death of a best friend during high school propelled her into social work. By the time she pursued a doctorate, she had 18 years of clinical social work experience, completed a clerkship, and was even appointed to the state's Board of Registration of Social Workers. But this didn't seem like enough. She noticed her peers would find supervisors with ease. Meanwhile, 'I always felt I had to prove myself.' 'What was I missing that they have?' Robinson Findlay said. 'And when you control for all the things, there's only one thing that pops out.' Learning about the craft is only the first hurdle to entering the industry. It costs hundreds for Mental health counselors, clinical social workers, psychologists, and other professionals within the field must complete thousands of hours to qualify for a license, some of which have to be under direct supervision from another practitioner. Labissiere said the onus for supervision is placed on the aspiring clinician; they must find someone who is willing to sign off on their application and in turn, lose an employee that keeps their own practice afloat. 'These are gatekeeper positions,' Labissiere said. 'If you don't have an organization ... pushing you to become licensed, we get stuck.' Advertisement Wynn worries this mentality might choke off the next generation of clinicians of color, which is already a small group. 'People look at it as competition, but there's more than enough clients in need,' Wynn said. 'It's not a competition. It's a collaboration.' While navigating the many stressors of entering the workforce, many aspiring social workers aren't taught the financial literacy needed to start and sustain independent practices, said Malaka Mims, president of the Greater Boston Association of Black Social Workers. So many social workers are focused on passing the exam, she said, that they often say, 'I don't know how to be a business owner.' 'Social workers are trained to help others, but the field must also prioritize self care and equip social workers to care for ourselves,' Mims said. For Robinson Findlay, of Upwards 'N' Onwards, running her own practice has been a longtime dream, but it comes with its own challenges. She has scaled her fees down to accommodate low-income clients, and says she is owed thousands in private insurance reimbursements. She makes up with consulting, lecturing, and a postdoctoral fellowship. Robinson Findlay can barely afford to do this, but she can't refuse a client's request. 'Even if I say no to one, that's too many.' This story was produced by the Globe's team, which covers the racial wealth gap in Greater Boston. You can sign up for the newsletter . Tiana Woodard can be reached at

Business Upturn

7 hours ago

• Business Upturn

Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

By GlobeNewswire Published on June 21, 2025, 04:34 IST Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions. 1,2 and presented at the American Diabetes Association (ADA) Scientific Sessions. Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet. 3 Findings from the clinical trials indicate amycretin appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2,3 Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule. The published and presented results from the once-weekly subcutaneous amycretin phase 1b/2a clinical trial showed that participants who received the treatment demonstrated significantly greater weight loss across the full range of doses investigated compared to placebo. Data being presented at ADA were collected from two parts of the trial; dose escalation (amycretin 60 mg), and dose escalation and maintenance (amycretin 20 mg, 5 mg and 1.25 mg).1,2 No plateauing in weight reduction was observed at the end of treatment (ranging from 20 to 36 weeks) with all tested doses, suggesting that a longer treatment duration may potentially contribute to additional weight loss.1,2 Estimated mean change in body weight from baseline with once-weekly subcutaneous (SC) amycretin: 1,2 * Dose Treatment % Weight change % Weight change duration (SC amycretin) (placebo) 60 mg 36 weeks -24.3% -1.1%20 mg** 36 weeks -22.0% 1.9%5 mg** 28 weeks -16.2% 2.3% 1.25 mg** 20 weeks -9.7% 2.0% * If all people adhered to treatment i.e. if all people followed the planned dosing schedule for the full trial period without any treatment discontinuations. ** Administered during a 12-week maintenance period. Once-weekly subcutaneous amycretin treatment escalated up to 60 mg appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2 The number of treatment-emergent adverse events (TEAEs) increased in a dose-dependent manner, were mostly gastrointestinal, and were comparable to the rate and profile of TEAEs reported in early-phase studies of GLP-1 receptor, GLP-1 receptor/gastric inhibitory polypeptide (GIP) receptor, and amylin receptor agonists.1,2 The majority of TEAEs were mild to moderate in severity and resolved by the end of the study period.1,2 Of the participants who discontinued the trial, the majority were due to non-TEAE reasons.1,2 'As pioneers in obesity innovation, we are exploring multiple biological pathways to develop potentially transformative medicines that support the individual needs and preferences of people with obesity on their weight loss journey towards overall improved health,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk . 'Amycretin is the first investigational treatment that combines GLP-1 and amylin receptor agonism biology in one molecule, working on distinct pathways and offering complementary effects on appetite control. The findings published and presented today are encouraging. We are excited to advance the clinical development of subcutaneous and oral amycretin into phase 3 to assess its potential as a therapeutic option for weight management.' The published once-daily oral amycretin phase 1 clinical trial data showed that participants receiving amycretin achieved greater weight loss compared to placebo.3 After 12 weeks of treatment with amycretin up to 50 mg and up to 2 times 50 mg, participants achieved a mean change in body weight of -10.4% and -13.1% respectively, compared to -1.2% with placebo.3 There were no apparent signs of weight loss plateauing within the 12 weeks of treatment in either of these amycretin-treated groups.3 Once-daily oral amycretin appeared to have an acceptable safety profile and was tolerable in all tested doses, with TEAEs in line with what was expected from targeting GLP-1 and amylin receptors.3 All reported TEAEs occurred in a dose-proportional manner, were mild to moderate in severity, and mostly gastrointestinal. No new safety signals appeared during the study.3 Based on the findings from the oral and subcutaneous amycretin trials, Novo Nordisk recently announced it will advance amycretin into phase 3 trials to further investigate the treatment as a potential new therapeutic option for weight management.4 About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral amycretin Phase 1 trial – The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in 144 people with overweight or obesity, with a total treatment duration of up to 12 weeks. Subcutaneous amycretin Phase 1b/2a trial – The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References The Lancet: Dahl K, Toubro, S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. Dahl, K, et al. (2025). Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist: Results of a Phase 1b/2a Clinical Trial. Poster 2002-LB. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025. The Lancet: Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study. Novo Nordisk Company Announcement. Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development. Available at: Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

8 hours ago

Diabetes drug may cut migraine days in half with little weight loss: Study

Drugs in the same family as Ozempic and Wegovy are known for treating diabetes and helping with weight loss, but a small, early-stage study suggested they might also ease migraines -- even when there's no weight loss. The benefit appears to come from lowering pressure in the brain, Dr. Simone Braca, a neurologist at the University of Naples Federico II and lead author of the study, explained to ABC News. 'This study is very interesting in that the GLP 1s are hypothesized to lower brain pressure, which can then lower your chance of getting a headache or a migraine,' Braca said. The small, 12-week study tracked 26 adults with obesity who had chronic or frequent migraines. Published in Headache -- the official journal of the American Headache Society -- and presented at this week's European Academy of Neurology meeting in Finland, it tested liraglutide, a type of GLP-1 drug commonly used for diabetes and weight loss. After taking a daily 1.8 mg dose of liraglutide for three months -- the amount typically used to treat diabetes -- their average number of headache days per month dropped from 20 to about nine. Participants also reported less disability from migraines, with scores on a standard headache impact scale cut by more than half. Although some participants lost a small amount of weight, Braca said the few lost pounds were not meaningful enough to explain the improvement in migraines. Instead, Braca pointed to pressure from cerebrospinal fluid -- the liquid that surrounds and cushions the brain and spine. He said he believes that even slight buildups of this fluid can press on nearby veins and nerves in the brain, potentially triggering migraines. 'An increased pressure of the spinal fluid in the brain may be one of the mechanisms underlying migraine,' Braca said. 'And if we target this mechanism, this preliminary evidence suggests that it may be helpful for migraine.' Nearly half of patients reported at least a 50% reduction in headache days, according to the Headache paper. About 40% experienced mild side effects like nausea or constipation. None stopped taking the medication. With such promising results, Braca and his research team, led by Dr. Roberto De Simone, are already planning larger trials. Future studies will measure brain pressure more directly and explore whether other GLP 1 drugs might also offer the same relief but with fewer side effects. 'There are still a substantial portion of migraine patients that face an unmet need and that live with its burden,' he said. 'New drugs that could target other pathways, I think that could be reassuring to those patients and give them hope.' The study adds to growing evidence that GLP-1 drugs may have benefits beyond diabetes and weight loss. Researchers are already studying these medications for a range of other conditions, including reducing the risk of heart disease and stroke, easing symptoms of addiction and treating Alzheimer's disease.